Seminars in Oncology
Volume 33, Issue 6 , Pages 642-646 , December 2006

Chemoprevention of Breast Cancer for Women at High Risk

  • Kathryn Chan
    • ,
  • Gloria J. Morris

      Affiliations

    • Corresponding Author InformationAddress correspondence to Gloria J. Morris, MD, PhD, Department of Medicine, Division of Medical Oncology, Jefferson Medical College, 125 S 9th St, Suite 801, Sheridan Building, Philadelphia, PA 19107.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Gail MH. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–1886
  3. Gail MH. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829–1846
  4. Spiegelman D, Colditz GA, Hunter DL, et al. Validation of the Gail et al model for predicting individual breast cancer risk. J Natl Cancer Inst. 1994;86:600–607
  5. Claus EB, Risch N, Thompason WD. Autosomal dominant inheritance of early onset breast cancer: Implications for risk prediction. Cancer. 1994;73:643–651
  6. Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002;20:3328–3343
  7. Fisher B. Tamoxifen for the prevention of breast cancer: A report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–1388
  8. Fisher B. Tamoxifen for the prevention of breast cancer: Current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 2005;97:1652–1662
  9. Cuzick J, Forbes J, Edwards R, et al. First results from the international breast cancer intervention study (IBIS-1): A randomized prevention trial. Lancet. 2002;360:817–824
  10. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 1998;352:98–101
  11. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen : Preliminary findings from the Italian randomized trial among hysterectomised women. Lancet. 1998;352:93–97
  12. Hartmann LC. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229–237
  13. Hershman D. Outcomes of tamoxifen chemoprevention for breast cancer in very high risk women: A cost effectiveness analysis. J Clin Oncol. 2002;20:9–16
  14. Tan-Chiu E. Effects of tamoxifem on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst. 2002;95:302–307
  15. Antoniou A. Average risk of breast and ovarian cancer awssociated with BRCA1 and BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130
  16. Metcalfe K. Contralateral brest cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328–2335
  17. Peshkin NF, Isaacs C. Evaluation and management of women with BRCA-1/2 mutations. Oncology. 2005;19:1451–1459
  18. Narod SA, Brunet JS, Ghadirian P, et al. Hereditary Breast Cancer Clinical Study Group Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet. 2000;356:1876–1881
  19. King MC. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: The National Surgical Adjuvant Breast and Bowel Project (NSABP-P-1) breast cancer prevention trial. JAMA. 2001;286:2251–2256
  20. Struewing JP, Watson P, Easton DF, et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Monogr. 1995;17:33–35
  21. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91:1475–1479
  22. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616–1622
  23. Olson JE, Sellers TA, Iturria SJ, et al. Bilateral oophorectomy and breast cancer risk reduction among women with a family history. Cancer Detect Prev. 2004;28:357–360
  24. Elmore JG, Gigerenzer G. Benign breast disease—The risks of communicating risk. N Engl J Med. 2005;353:297–299
  25. Raloxifene for postmenopausal osteoporosis. Med Lett Drugs Therapeutics. 1998;40:29
  26. Ettinger B, Black DM, Mitlake BH, et al. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA. 1999;28:637–645
  27. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. JAMA. 1999;281:2189–2197
  28. Martino S, Cauley JA, Barrett-Connor E, et al. CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751–1761
  29. Vogel VG. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin Cancer Res. 2001;7:4413s–4418s
  30. Vogel VG, Costantino JP, Wickerham DL, et al. The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer. 2002;3:153–159
  31. Raloxifene (Evista) for breast cancer prevention in postmenopausal women. Med Lett Drugs Therapeutics. 2006;48:1234
  32. Mosca L, Barrett-Connro E, Wenger NK, et al. Design and methods of the Raloxifene Use for the Heart (RUTH) study. Am J Cardiol. 2001;88:392–395
  33. Decensi A, Galli A, Veronesi U. HRT opposed to low-dose tamoxifen (HOT study): Rationale and design. Recent Results Cancer Res. 2003;163:104–111
  34. Baum MBA, Cuzick J, Forbes J, et al. ATAC Trialists’ Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet. 2002;359:2131–2139
  35. Baum MBA, Cuzick J, Forbes J, et al. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802–1810

PII: S0093-7754(06)00328-9

doi: 10.1053/j.seminoncol.2006.08.017

Seminars in Oncology
Volume 33, Issue 6 , Pages 642-646 , December 2006

Article Tools

* Image Usage & Resolution